Introduction
Naïve CD4 + T-lymphocytes, upon stimulation with antigens in the appropriate environment, differentiate into two classes of effector cells, T H 1 and T H 2. Increased numbers of CD4 + T-cells expressing IL-4 and IL-5 mRNA have been found in bronchoalveolar lavage (BAL) [1] [2] [3] and in nasal and bronchial mucosa 4, 5 from allergic subjects. It has been demonstrated that peripheral blood lymphocytes from asthmatic subjects are primed for enhanced productions of IL-4 and IL-5 mRNA 6 and GATA-3 DNA 7 indicating a T H 2-predominance in asthma. IFNg, a major cytokine from T H 1 cells, directly suppresses IgE synthesis and inhibits the development toward T H 2 cells. 8, 9 In young children with atopic disease, the reduction of IFNg secretion was demonstrated. 10, 11 Infants whose cord blood cells had shown diminished IFNg production in vitro were susceptible to the subsequent development of atopy. 12 Furthermore, T H 1-cells produce IFNg to participate in cellmediated immunity that controls infection by intracellular pathogens. The predominant factors that control T H 1 differentiation are cytokines such as IL-12 to stimulate and IL-4 to inhibit T H 1 differentiation.
The transcription factor T-box-expressed-in-T-cells (T-bet) has recently been described as a T H 1-specific factor that plays a central role in T H 1 differentiation. 13 T-bet was described as a controller of T H 1 development and was shown to have direct effects in IL-12 receptor b 2 chain expression and IFNg production. [14] [15] [16] [17] Additionally, transfection of T-bet into T H 2 cells induced high levels of IFNg and suppressed IL-5 and IL-4 generation. 18 Finotto et al. 19 described reduced numbers of cells staining for T-bet in bronchial biopsy specimens from asthmatic patients. Furthermore loss of T-bet results in increased airway hyperreactivity (AHR), an increased peribronchial and perivascular infiltration of eosinophils and lymphocytes, a greater amount of collagen around the airways and increased immunostaining of myofibroblasts in the airways of mice deficient in T-bet. So the authors speculate that a defect in T H 1 development through a deficiency in T-bet might predispose to T H 2-responses.
However, recent data argue against this model.
20-22
Ylikoski et al. 23 reported that in normal human cord blood IL-12 signaling is able to induce T-bet mRNA and protein expression during the early polarization of human CD4 + T-cells to T H 1 direction and a likely mechanism behind it is IL-12 induced STAT1 tyrosine phosphorylation. Recently, Hwang et al. 24 reported that T-bet represses T H 2 lineage commitment through tyrosine kinase-mediated interaction between the two transcription factors that interferes with the binding of GATA-3 to its target DNA providing a novel function for tyrosine phosphorylation of T-bet and revealed that the role of T-bet tyrosine phosphorylation in repressing T H 2 cytokines is independent of IFNg. Moreover, Usui et al. 20, 25 could demonstrate in mice that naïve T-cells tend toward T H 2 differentiation through induction of GATA-3 and subsequent down-regulation of STAT4/IL-12Rb2 chain unless GATA-3 levels or function is regulated by T-bet indicating that the principal function of T-bet in developing T H 1 cells is to negatively regulate GATA-3 rather than to positively regulate IFNg gene. They also could shown that developing T H 2 cells from T-bet À/À mice could differentiate into T H 1 cells when STAT4 and IL-12Rb2 chain expression are maintained. 25 Regulation of transcription of immunomodulatory and inflammatory genes such as T-bet in response to extracellular stimuli is achieved by a variety of different signal transduction mechanisms. One of the most extensively studied signaling pathways into the nucleus involves the mitogen-activated protein (MAP) kinase (MAPK) cascade. 26 At present there are at least three MAP kinase pathways which are defined according to the MAP kinase that is activated (a) the extracellular signal regulated protein kinase (ERK)-1 and -2 pathway, (b) the c-Jun N-terminal protein kinase (JNK) pathway and (c) the p38mitogen-activated protein kinase (p38MAPK) pathway. These are activated by different stimuli including growth factors, endotoxins, stress, pharmacological agonists and cytokines such as IL-12.
27,28 A number of recent studies have demonstrated a major role for the components of the MAPK pathway in the regulation of innate and adaptive immune responses including T H 1/T H 2 differentiation 29,30 but little is known about the modulatory role of the MAPkinases ERK-1/-2 and p38MAPK on T-bet and IFNg expression of human peripheral blood T-lymphocytes.
Corticosteroids constitute the most effective current antiinflammatory therapy for acute and chronic forms of allergic diseases and asthma. Corticosteroids are highly effective in inhibiting the effector function of epithelial cells, eosinophils and T H 2 cells and also in inducing T-cell apoptosis. 31, 32 These results are seemingly in conflict with a previous study by Cannarile et al. 33 reporting that glucocorticoid-induced leucine zipper (GILZ), induced by dexamethasone, is involved in control of T lymphocyte activation and apoptosis using GILZ transgenic mice which overexpress GILZ in the T-cell lineage. Interestingly, those cells secrete more T H 2 cytokines (IL-5, IL-13, IL-4) and produce less T H 1 cytokines (IFNg) than wild-type mice. Upregulation of T H 2 cytokine expression correlated with increased expression of T H 2 specific transcription factors (GATA-3) and decreased expression of T-bet indicating that GILZ is implicated in T H 2 response development and may be one critical mechanism accounting for glucocorticoid immunomodulation. 33 In the present study, the potential role of the protein kinases ERK-1/-2 and p38MAPK and dexamethasone in modulating T-bet expression and IFNg release in human peripheral T-lymphocytes were examined. As T-bet may be a potent inducer of the T H 1 specific cytokine IFNg, we were interested in measuring whether the amount of IFNg corresponds to their T-bet expression levels and compared normal and asthmatic individuals.
Materials and methods

Subjects
The study population consisted of 10 healthy non-atopic non-smoking volunteers (four males, six females; mean age: 30.772.4 years), who had no history of asthma or of any respiratory disease with normal lung function and airway responsiveness to methacholine (PC 20 416 mg/ml) and 10 mild atopic asthmatics (five males, five females; mean age: 28.872.8 years) with an airway hyperresponsiveness to methacholine (PC 20 o8 mg/ml); positive PRICK-or RASTtests for house dust mite etc. were included in this study ( Table 1 ). All volunteers underwent peripheral blood separation after giving written informed consent. The study was approved by the Ethics Committee of the University of Cologne.
Isolation of human peripheral blood lymphocytes
A total of 50 ml of peripheral venous blood from 10 nonatopic normals and 10 atopic asthmatics were drawn into sterile syringes (Becton Dickinson, Franklin Lakes, NY, cat# 300296) by veinpuncture with anticoagulant-citrate-dextrose (ACD) solution as anticoagulant at a final concentration of 10% (v/v). (ACD: 277 mM D-(+)-glucose; 142 mM tribase sodium citrate). In parallel total venous blood (2 ml) from all subjects were submitted to the laboratory for differential WBC count ( Table 1 ).
The ACD-blood was prepared for sedimentation using 20 ml of ELO-HES (6-hydroxyethyl starch) and 5 ml of ACD (10%) per 25 ml of ACD-blood. The tubes were inversionly mixed and air bubbles removed to prevent cell activation before leaving at room temperature for sedimention of cells on a vibration free surface for approximately 60 min. The leukocyte-rich plasma fraction was centrifuged at 360g for 10 min and 4 1C. The cell pellet was washed twice and then resuspended in about 2 ml of Hank's balanced Salt Solution (HBSS, Sigma, St. Louis, MO, cat# H6648). and layered over 7 ml of Ficoll-paque (Amersham Pharmacia Biotech, Uppsala, Sweden, cat# 17-1440-02) and centrifuged for 30 min at 360g and 18 1C. The band of mononuclear cells (monocytes and lymphocytes) were collected from the interface and washed and resuspended three times in HBSS (Hanks buffered saline solution). After the third wash the cells were resuspended in RPMI 1640 (Sigma, cat# R-7638), supplemented with 10% fetal calf serum (FCS; Sigma, cat# N-4637), 2 mM L-glutamine, 100 U/ml penicillin, 100 m/ml streptomycin (all from Sigma, Munich, Germany). Lymphocytes were separated from monocytes by depletion of monocytes by plastic adherence seeding in a culture flask in culture RPMI1640 medium in a humified atmosphere with 5% CO 2 for 3 h. After 3 h, nonadherent cells (lymphocytes) were separated and used for further analysis. The proportion of CD 3+ -lymphocytes in this separated cell fraction was examined by FACS-analysis. The purified T-lymphocytes from mononuclear cell (MNC) samples were routinely X98% CD3 + lymphocytes. Cells were 485% viable, as assessed by trypan blue exclusion.
FACS analysis
Purified T-lymphocytes from mononuclear cells were incubated with CD14 + conjugated PE-Ab and CD3 + conjugated FITC-Ab and analyzed by flow cytometry in each test. Cells were initially gated on the basis of forward scatter and side scatter characteristics, with gates set to remove debris. Results were expressed as a percentage of cells exhibiting positive fluorescence (data not shown).
Cell culture
Peripheral blood T-lymphocytes were cultured at 37 1C in a humified atmosphere with 5% CO 2 in RPMI1640 medium (Sigma, Munich, Germany) supplemented with 10% (v/v) FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 m/ml streptomycin (all from Sigma, Munich, Germany). After 12 h cells were stimulated in fresh RPMI medium as above at 1 Â 10 6 cells/ml for ELISA and with RPMI medium in the absence of FCS at 3 Â 10 6 cells/ml for real-time-PCR and for Western blotting. CD3-purified mouse anti-human monoclonal antibody; (500 ng/ml; BD Becton Dickinson, Heidelberg, Germany; cat# 555336) and CD28-purified mouse antihuman monoclonal antibody (500 ng/ml; BD Biosciences; Germany, cat# 555725) were added 30 min before stimulation with IL-12 (10 ng/ml; R&D Systems, Wiesbaden, Germany; cat# 219-IL-005) for 72 h for ELISA and for 4 h for real-time-PCR. The ERK-1/-2 inhibitor, PD 098059 (10 mM; Calbiochem-Merck, Darmstadt, Germany, cat# 513000), the p38MAPK inhibitor SB 203580 (10 mM; Calbiochem-Merck, Darmstadt, Germany; cat# 559389) and dexamethasone (10 À6 M; Sigma-Aldrich, Munich, Germany, cat# D-4902) were added 30 min before stimulation with IL-12. Drugs were dissolved in dimethyl sulfoxide (Me 2 SO) or distilled water and were diluted to final concentrations of less than 0.1% (v/v). Me 2 SO alone had no effect on expression or generation of IFNg, T-bet or EF-1a (data not shown). We have done time-and concentration-dependent experiments for all treatments used.
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Enzyme-linked immunosorbent Assays (ELISA) for IFNc
IFNg was assayed using a quantitative sandwich enzyme immunoassay technique. 96-well plates (NUNC Inc) were coated overnight at room temperature with 100 ml of a monoclonal anti-human IFNg antibody (2 mg/ml) (R&D Systems; Wiesbaden, Germany; cat# MAB285). After washing with TBS-Tween-20 s , the antibody was blocked with PBS/1% BSA; 5% sucrose (Sigma, Munich, Germany) and 0.05% NaN 3 (300 ml/well, Sigma, Munich, Germany) for 1 h. IFNg-standard (rh IFNg, R&D Systems, cat# 285-IF-100) and a biotinylated secondary anti-human IFNg antibody (R&D Systems; cat# BAF285) non-diluted samples were added to the plate for 2 h at room-temperature and washed with PBSTween-20 s four times. A biotinylated secondary anti-human IFNg antibody (R&D Systems; cat# BAF285) (100 ml of 125 ng/ ml) in PBS/1% BSA was added for 1 h followed by 100 ml streptavidin-HRP (R&D Systems, cat# DY998). After washing, 100 ml of TMB substrate solution (Sigma, Munich, Germany; cat# T8665) and 50 ml stop solution (1 M H 2 SO 4 ) (AppliChem, Darmstadt, Germany, cat# A2699) was added to each well and IFNg was measured colorimetrically at 450 nm and quantified by interpolation from a standard curve. The lower limit of detection was 16 pg/ml.
RT-Real time PCR for T-bet and elongation factor (EF)-1a
RNA isolation and cDNA synthesis RNA of T-lymphocytes (3 Â 10 6 cells) was extracted using Qiagen kit (RNeasy Mini kit, Qiagen, Hilden, Germany, cat# 74106), according to the manufacturer 0 s instructions and RNA was finally eluted in 30 ml nuclease free water. The concentration and purity of RNA were assessed by spectrophotometry. 10 mg of RNA was treated with DNase (Promega Corporation, Madison, WI, USA; cat# M610A) at 37 1C for 15 min. After addition of 2 ml of stop solution (Promega Corporation, Madison, WI, USA cat# M199A) RNA was heat inactivated at 65 1C for 10 min. Reverse transcription of 0.5 mg of DNase treated RNA was performed using random hexamers (Promega Corporation, Madison, WI, USA; cat# C1181) and Omniscript RT kit (Qiagen, Hilden, Germany, cat# 205 111) according to the manufaturer's instruction and samples were incubated at 37 1C for 60 min followed by 93 1C for 5 min. The cDNA was subsequently diluted to a final volume of 60 ml with nuclease-free water.
Standard-plasmid construction
We generated plasmid-standards to quantify the gene expression. Plasmids containing a gene region of the T-bet or EF-1a genes were created by PCR-mediated cloning. A backbone pBluescript SK-plasmid (Stratagene, La Jolla, CA, USA, cat# 212206) was linearized with BamHI and dephosphorilized. For the insert production the amplification primer pairs for the real-time PCR (see below) were used supplemented with a BamHI-restriction site at the 5 0 end. With these primers a conventional 3-step PCR on a lymphocyte cDNA was performed. The obtained inserts were purified by a gel extraction and followed by a BamHI digest to obtain sticky ends. The inserts were cloned into the linearized plasmid-backbone. Subsequently we performed a functional test with the real-time PCR. The concentration of plasmid-DNA was assessed by spectrophotometry and the copy number was calculated. Standard curves for each gene were generated using 10-fold serial dilutions (10 2 -10 5 copies/4 ml) including a no template control.
Real-time PCR
Our initial plan to use the expression level of GAPDH in normalizing the results of T-bet failed. These results were consistant with those of Hamalainen et al. 34 demonstrating that the transcription of a constitutively expressed gene in human CD4
+ T-cells may change during cell culture in vitro and this was most pronounced with b-actin (up to 11.4-fold) and GAPDH (up to 17.0-fold). In contrast the expression of EF-1a and UbcH5B remained constant during the entire culture periods. 34 Therefore, EF-1a was used in this study to normalize the T-bet expression.
For real-time PCR, the following intron spanning primer pairs were used: T-bet forward primer: 5 0 -GAT CAT CAC CAA GCA GGG ACG-3 0 , T-bet reverse primer: 5 0 -TCC ACA CTG CAC CCA CTT GC-3 0 , with an amplification length of 154 bp. EF-1a forward primer: 5 0 -GGG ATG GAA AGT CAC CCG TA-3 0 , EF-1a reverse primer: 5 0 -GCC GTG TGG CAA TCC AAT-3 0 , with an amplification length of 461 bp (all from VBC-Genomics Bioscience Research GmbH, Vienna, Austria). Real time PCR reaction contained 4 ml cDNA, 0.5 mM forward and reverse primer for T-bet or EF-1a, 4 ml LC-FastStart DNA Master plus SYBR Green I-mix (Roche Diagnostics GmbH, Mannheim, Germany cat# 03515885001) and was diluted with nuclease free water to a final volume of 20 ml. cDNA samples, the plasmid-standards and one no-template control were measured for each gene analysis. PCR amplification and quantification were performed in a LightCycler TM 1.5 instrument (Roche Diagnostics, GmbH, Mannheim, Germany). After an initial denaturation at 95 1C for 10 min, a three step PCR was performed for 40 cycles: (1) denaturation at 95 1C for 10 s; (2) annealing at 60 1C for 5 s and (3) extension at 72 1C for 7 s for T-bet and 20 s for EF-1a. Fluorescence was detected at the end of each extension step (SYBR Green format). Melting analysis was performed following template amplification as a specific control. Therefore, the amplified product was slowly heated (0.1 1C/s) from 65 to 95 1C and fluorescence was measured continuously. Data evaluation was performed using LightCycler TM software version 3.5 according to the suppliers recommendations. Sample concentration was calculated using standard curve with plasmid DNA template for each gene. Relative gene expression was expressed as a ratio of T-bet copies to EF-1a copies.
Sodium dodecyl sulphate-gel electrophoresis and Western blotting
The status of T-bet and GAPDH were assessed by Western immunoblot analysis using antibodies that recognize T-bet and GAPDH proteins. Cell pellets were lysed with mammalian cell lysis kit (Sigma, Munich, Germany; cat# MCL1-1KT) and denatured proteins (30 mg supplemented with 1% nonfat milk for T-bet and also for GAPDH, and subsequently visualized by ECL. The relevant bands were quantified using a transilluminator with a light converter plate (coupled with video camera and computer), BioDocAnalyze 2.0 software (Biometra, Göttingen, Germany) normalized to the house-keeping protein GAPDH.
Data analysis
Data are represented as mean7SEM. Data were analyzed by Student's t-test for paired data or by one-way ANOVA/ Bonferroni multiple comparison test. The null hypothesis was rejected when Po0:05.
Results
IL-12-induced T-bet mRNA expression (real time PCR)-effect of PD 098059, SB 203580 and dexamethasone
There was no significant difference in basal (non-stimulated) and anti-CD3/anti-CD28-pretreated T-bet mRNA expression normalized to EF-1a in normal and asthmatic T-cells (T-bet/ EF-1a ratio normals: basal: 0.004470.0015; anti-CD3/anti-CD28: 0.0170.003, n ¼ 10; T-bet/EF-1a ratio asthmatics: basal: 0.004170.0005; anti-CD3/anti-CD28: 0.01170.0022; P40:05; n ¼ 10; Fig. 1 ).
IL-12 (10 ng/ml) induced an increase in T-bet mRNA expression of anti-CD3/anti-CD28 pretreated T-cells from asthmatics compared with normals (0.03370.009 vs. 0.01270.0024.; n ¼ 10; Po0:05). Stimulation with IL-12 (10 ng/ml) did not induce further T-bet mRNA expression of anti-CD3/anti-CD28 pretreated T-cells from normals (0.01270.0024 vs. 0.0170.003; n ¼ 10; P40:05).
PD 098059 (10 mM) had no inhibitory effect on IL-12-induced increased T-bet mRNA expression in T-cells from asthmatics (0.03370.01; P40:05, vs. IL-12 alone; n ¼ 10).
However, the inhibition of the increased IL-12 induced T-bet mRNA expression in T-cells from asthmatics by SB 203580 (10 mM) was $100% (0.015370.007 vs. 0.03370.009; Po0:05; n ¼ 10), indicating that p38MAPK pathway may play a more basic role in the regulation of T-bet transcription in asthma.
Dexamethasone (10 À6 M) reduced IL-12-induced T-bet mRNA expression in asthmatic T-cells nearly completely (T-bet/EF-1a ratio: 0.009970.002 vs. 0.03370.009, Po0:05; n ¼ 10); (Fig. 1) . PD 098059 and SB 203580 did not modulate the dexamethasone-induced inhibition of T-bet mRNA expression in T-cells from asthmatics and normals (Fig. 1) .
IL-12-induced T-bet protein expression (Western blotting)-effect of PD 098059, SB 203580 and dexamethasone
Under basal (non-stimulated; data not shown) and under anti-CD3/anti-CD28 pre-treated conditions, expression of T-bet was detectable by Western blotting (Fig. 2) and was normalized to the house-keeping protein GAPDH (Fig. 2) .
IL-12 (10 ng/ml) induced a significant increase in T-bet expression in asthmatic T-cells compared with normals (T-bet/GAPDH ratio: normals: 0.1970.03 vs. asthma: 0.5770.1; n ¼ 10, Po0:05).
PD 098059 (10 mM) had no inhibitory effect on IL-12-induced increased T-bet protein expression in asthmatic T-cells (0.7670.2 vs. 0.5770.1; P40:05, n ¼ 10). However, the inhibition of the increased IL-12 induced T-bet protein expression in T-cells from asthmatics by SB 203580 (10 mM) was $80% (0.2170.04 vs. 0.5770.1; Po0:05; n ¼ 10), indicating that p38MAPK pathway may play also a more basic role in the regulation of T-bet expression on posttranscriptional level in asthma.
Dexamethasone (10 À6 M) reduced IL-12-induced T-bet protein expression in asthmatic T-cells nearly completely (T-bet/GAPDH ratio: 0.1470.04 vs. 0.5770.1, Po0:05; n ¼ 10); (Fig. 2) . PD 098059 and SB 203580 did not modulate the Dexamethasone-induced inhibition of T-bet protein expression in T-cells from asthmatics and normals (Fig. 2) .
IL-12-induced generation of IFNc-effect of PD 098059, SB 203580 and dexamethasone
There was no difference in the basal and anti-CD3/anti-CD28-pretreated generation of IFNg in human peripheral blood T-lymphocytes from adult atopic asthmatics (anti-CD3/anti-CD28: 305.37131.8 pg/ml; n ¼ 10) compared with adult non-atopic normals (anti-CD3/anti-CD28: 273.27 111.2 pg/ml; n ¼ 10; graph not shown). IL-12 (10 ng/ml) induced an increase in IFNg release in T-cells and this to the same extent in normals (714.97233.0 pg/ml; n ¼ 10) and in the asthmatics (732.77354.7 pg/ml; n ¼ 10; P40:05) (graph not shown).
PD 098059 (10 mM), an inhibitor of the upstream activator of ERK-1 and ERK-2, suppressed IL-12-induced IFNg release by 41.174.5% in T-cells from normals but only by 20.976.3% in asthma (Po0:05; n ¼ 10; Fig. 3) indicating a diminished T H 1-related ERK-modulation in asthma. SB 203580 (10 mM), an inhibitor of the a-and b-isoform of p38MAPK, was more effective on IFNg release, causing an inhibition of
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Effect of MAPkinases and dexamethasone on T-bet-and IFNg-production from asthmatic T-lymphocytes53.877.4% in T-cells from normals and 64.375.1% in T-cells from asthmatics without statistical significance between both groups (n ¼ 10; P40:05; Fig. 3 ).
Dexamethasone (10 À6 M) inhibited IL-12-induced IFNg release by 34.5710.8% in T-cells from normals (n ¼ 10) and by 52.1717.3% in asthmatics (n ¼ 10; P40:05; Fig. 3 ). Interestingly, there was an additional inhibitory effect on IFNg release when PD 098059 or SB 203580 were added in the presence of dexamethasone and this was statistically significant by SB 203580 in T-cells from normals (74.777.1% vs. 34.5710.8%; Po0:05; n ¼ 10; Fig. 3 ).
Discussion
In this study, we could shown that the T H 1-specific transcription factor T-bet was constitutively expressed in peripheral blood T-lymphocytes without differences between non-atopic normals and atopic asthmatic volunteers. Furthermore, we demonstrated for the first time that the I L-12-induced T-bet mRNA-and protein expressions were significantly increased in asthmatic peripheral blood T-cells compared with normals.
Interestingly, the elevated T-bet expression seen in asthmatic but not in normal T-cells did not correspond to the increased IFNg release seen in both groups. So we speculate that (1) IL-12 signaling is able to induce IFNg production independently of T-bet mRNA and protein expression in T H 1 cells and/or (2) IL-12 receptor b2 chain and/or STAT4 expressions could be down-regulated in asthmatic T-cells by elevated GATA-3 expression 7, 20, 25 and/ or (3) elevated GATA-3 expression in asthma 7 may inhibit IFNg expression 20 (Fig. 4) . Our results are consistant with a study from Ylikoski et al. 23 demonstrating that a high T-bet protein expression in human CD 4+ T-cells from the cord blood of healthy neonates does not necessarily correlate with IFNg production.
Moreover, Usui et al. 20, 25 could shown that naïve T-bet À/ À CD 4+ T-cells from mice were able to produce IFNg, and that the IFNg promoter accessibility could proceed in the absence of T-bet under IL-12 and anti-IL-4 stimulation. This could be one explanation why in our study IL-12 stimulation was followed by an increase in IFNg release but without increase in T-bet expression seen in normal T-cells, indicating that IL-12 did skew naive Th cells towards T H 1 although it did not augment T-bet.
Recently, Usui et al. 25 could demonstrate that naïve T-cells from mice tend toward T H 2 differentiation through induction of GATA-3 and subsequent down-regulation of STAT4/IL-12Rb2 chain unless GATA-3 levels or function is regulated by T-bet. The authors therefore supposed that the principal function of T-bet in developping T H 1 cells may be to negatively regulate GATA-3 rather than to positively regulate the IFNg gene.
Demonstrating that T-bet is not essential for IL-12Rb2 chain expression, Afkarian et al. 21 suggest that T-bet has an indirect influence on such expression through its ability to obviate GATA-3 effects on STAT4. Indeed, Usui et al. have shown that STAT4 signaling can induce IL-12Rb2 chain expression in the absence of T-bet and that GATA-3 down-regulation of the IL-12Rb2 chain occurs through downregulation of STAT4. 20, 25 It is well known, that GATA-3 expression is increased in asthmatic T-cells. 7 We speculate that elevated GATA-3 levels in asthma were followed by elevated T-bet expression seen in our study to further negatively regulate GATA-3 in asthma (Fig. 4) . Indeed, Erpenbeck et al. 22 reported that in healthy control subjects, the expressions of GATA-3, c-maf and T-bet in BAL cells were unchanged after saline or allergen challenge. In contrast, GATA-3, c-maf and T-bet were significantly upregulated after allergen challenge but not saline challenge in the asthmatic patients. This was surprisingly, because they expected a down-regulation of T-bet after allergen challenge in asthmatic T-cells, but the opposite was the case. The authors speculate that increased T-bet expression after allergen challenge in asthma might not only result from activated T H 1 but also from activated T H 2 cells and suggest that T-bet mRNA is not specific for a T H 1-type inflammatory response.
Interestingly, Höhler et al. 35 reported that the T H cell polarization and differentiation of T H 1 cells may under the control of cytokines and transcription factors with mainly locally and genetically determined activity. Signature cytokines and cytokine signaling events of T H 1 rather than T H 2 cells may be genetically determined and implicate that T H 2-associated diseases in humans such as asthma might be due to genetic variations in T H 1 cytokine regulation via T-bet. Höhler et al. have done a twin study and found low variability of intrapair differences in monozygotic (MZ) twins compared with dizygotic (DZ) twins for IFNg and T-bet, indicative of a strong genetic component in the expression of these T H 1-associated proteins. There was in contrast little or no evidence for a genetic effect on T H 2 differentiation, however. The fact that IL-12 stimulation was followed by an increase in T-bet expression of asthmatic T-cells but not in normals, as seen in our study, highlights this genetically determined mechanism further on T H 1 level.
We speculate that the increased GATA-3 expression in asthmatic T-cells were followed by a decrease in STAT-4 expression and this was followed by an increased downregulation of IL-12Rb2 chain expression responsible for no further increase in IFNg release compared with normals. 7, 20, 25 This could be one possible explanation why changes in T-bet mRNA between naïve and asthmatic T-cells did not correspond to changes in IFNg production seen in our study. Moreover, elevated GATA-3 levels might downregulate IFNg expression in asthmatic T-cells while increasing IL-4 and IL-5 expression. 36 We next investigated the role for phosphorylation of extracellular signal-regulated kinases (ERKs) ERK-1, ERK-2 and p38MAPK by studying the ability of their respective inhibitors PD 098059 and SB 203580 to regulate T-bet mRNA transcription and protein expression and IFNg release.
Evidence for this possibility has recently come from Agrawal et al. 37 who have shown that ERK 1 À/À mice display a bias toward T H 1 type immune response with higher IFNg production and lower IL-5 production in MOG35-55-primed T-cells indicating that ERK1 may modify the T H 1/T H 2 balance in T-cells as a negative regulator of T H 1 immune responses.
Whereas PD 098059 had no inhibitory effect on IL-12-induced T-bet expression in asthmatic and normal T-cells (Fig. 1 ) but decreased IFNg release by $40% in asthmatic and to a lesser extent in normal T-cells ($20%) (Fig. 3) , the inhibitory effect of SB 203580 on IL-12 induced T-bet mRNA and protein expression in asthmatic T-cells was $100% (Figs. 1 and 2 ). In contrast there was no inhibitory effect of SB 203580 on T-bet expression in normal T-cells but SB 203580 decreased IFNg release by $60% and this without differences between groups, indicating that (1) p38MAPK pathway rather than ERK-pathway may play a more basic role in the regulation of T-bet transcription and protein expression in asthma and (2) that ERK-and p38MAPK activation may modulate the IFNg expression independently of the T-bet signaling pathway and this regulatory role of ERK-1/-2 on IFNg release may impaired in asthma. IL-12 (10 ng/ml) had no effect on T-bet expression but promotes T H 1 response through an increase in IFNg release. There was a decrease in IL-12 induced IFNg release but no effect on T-bet expression in the presence of the specific ERK-inhibitor PD 098059 (10 mM), the specific p38MAPK-inhibitor SB 203580 (10 mM) and dexamethasone (DEX; 10 À6 M). Panel B: Stimulation with IL-12 (10 ng/ml) increased T-bet expression in asthmatic T-cells and this could be inhibited nearly completely in the presence of SB 203580 (10 mM) and Dex (10 À6 M). IL-12 induced an increase in IFNg release in asthmatic T-cells and this to the same extent as in normals. In contrast PD 098059 (10 mM) did not modulate the elevated T-bet expression in asthma. In the presence of SB 203580 (10 mM) and DEX (10 À6 M) the IFNg release was reduced and this to the same extent as in normals. In contrast PD 098059 (10 mM) modulated IFNg release in asthma to a lesser extent compared with normals. We speculate that increased GATA-3 levels in asthmatic T-cells decreased STAT-4 expression followed by a decrease in IL-12 receptor b2 chain expression, and therefore no additional increase in IFNg release could be found compared with normals. This is consistant with previous findings by Duan et al. 38 reporting that ERK activity in asthmatic mice was significantly higher as compared with normal mice. Moreover, they could show that a selective inhibitor of MAPK/ERK kinase U0126 suppressed OVA-induced airway hyperresponsiveness to inhaled methacholine in an in vivo mouse asthma model and reduced the serum levels of total IgE, lung tissue eosinophilia, airway mucus production and expression of VCAM-1 in lung tissues, implicating that inhibition of ERK-signaling pathway may have potential anti-inflammatory effects and therefore the authors speculate for a therapeutic potential for the treatment of allergic airway inflammation. 38 Corticosteroids are the most effective anti-inflammatory therapy for asthma. The predominant effect of corticosteroids is to switch off multiple inflammatory genes encoding cytokines and other mediators that have been activated during the inflammatory process. There is been considerable interest in how corticosteroids affect the T H 1-specific T-bet signal transduction pathway including the IFNg release in T-cells from normals and asthmatics.
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In this study, we could demonstrate that dexamethasone reduced the increased IL-12-induced T-bet mRNA expression in asthmatic T-cells nearly completely without additional effects of the specific MAPkinase inhibitors PD 098059 and SB 203580 (Fig. 1) . However, dexamethasone reduced the IFNg release only by $50% in asthmatic and normal T-cells indicating that (1) IFNg is regulated not only by T-bet but also by additional pathways and (2) that the inhibitory effect of dexamethasone on T-bet expression is increased in asthma. In the context of our speculation, that an increase in T-bet expression may be necessary to counter-regulate the increased GATA-3 level in asthma, the ''anti-inflammatory'' effect of dexamethasone on T H 1 response should be seen more critically and needs to be further investigated.
Furthermore, an additional inhibition of IFNg release was obtained when PD 098059 or SB 203580 were added to dexamethasone, indicating that inhibition of p38MAPK and of ERK-1/-2 pathways could potentiate the inhibitory effect of dexamethasone on IFNg release. This is consistent with findings from Tsitoura et al. 39 demonstrating that dexamethasone effectively suppressed T-cell receptor (TCR)-induced proliferation of naïve CD4 + T-cells. However, enhancement of TCR signaling by CD28-mediated costimulation abrogated the suppressive effect of dexamethasone. In particular, costimulatory signaling via ERK was essential for the development of T-cell resistance to dexamethasone, because selective blockade of ERK signal transduction abolished the costimulation-induced resistance. The authors speculate that, in the immune system, by regulating the degree of local costimulation through ERK can modify the effect of glucocorticoids on T-cells. 39 In conclusion, the therapeutic benefit of inhibitors of the ERK-and p38MAPK pathways and of the anti-inflammatory drug dexamethasone on T H 1-specific T-bet expression and IFNg release in asthma seems to be critical and needs to be further investigated.
